Clinical baseline factors predict response to natalizumab: their usefulness in patient selection

[1]  J. Sargento-Freitas,et al.  Clinical predictors of an optimal response to natalizumab in multiple sclerosis , 2013, Journal of Clinical Neuroscience.

[2]  C. Pozzilli,et al.  Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis , 2012, Journal of the Neurological Sciences.

[3]  L. Grimaldi,et al.  Urinary JCV-DNA Testing during Natalizumab Treatment May Increase Accuracy of PML Risk Stratification , 2012, Journal of Neuroimmune Pharmacology.

[4]  Meena Subramanyam,et al.  Risk of natalizumab-associated progressive multifocal leukoencephalopathy. , 2012, The New England journal of medicine.

[5]  H. Norton,et al.  Course of relapsing–remitting multiple sclerosis before, during and after natalizumab , 2011, Multiple sclerosis.

[6]  J. L. Poveda-Andrés,et al.  Evaluación de la efectividad y la seguridad del natalizumab en el tratamiento de la esclerosis múltiple remitente recidivante , 2011 .

[7]  G. Moonen,et al.  Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing‐remitting multiple sclerosis , 2011, European journal of neurology.

[8]  E. de Ramón,et al.  The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational study , 2011, Multiple sclerosis.

[9]  G. Fenu,et al.  The cohort of the multiple sclerosis center of Cagliari , 2011, Neurological Sciences.

[10]  T. Olsson,et al.  A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis , 2011, Multiple sclerosis.

[11]  Michael Hutchinson,et al.  New perspectives in the natural history of multiple sclerosis , 2010, Neurology.

[12]  M. Calabrese,et al.  No evidence of JC virus reactivation in natalizumab treated multiple sclerosis patients: an 18 month follow-up study , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[13]  N. Putzki,et al.  Efficacy of natalizumab in second line therapy of relapsing–remitting multiple sclerosis: results from a multi‐center study in German speaking countries , 2010, European journal of neurology.

[14]  G. Comi,et al.  The pharmacovigilance program on natalizumab in Italy: 2 years of experience , 2009, Neurological Sciences.

[15]  N. Putzki,et al.  Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis , 2009, European journal of neurology.

[16]  G. Tedeschi,et al.  Natalizumab: a country-based surveillance program , 2008, Neurological Sciences.

[17]  G. Antonelli,et al.  Predicting beta-interferon failure in relapsing-remitting multiple sclerosis , 2007, Multiple sclerosis.

[18]  S. Martínez-Yélamos,et al.  Regression to the mean in multiple sclerosis , 2006, Multiple sclerosis.

[19]  Ludwig Kappos,et al.  A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[20]  B. Casanova,et al.  Assessment of the effectiveness and safety of natalizumab for treating relapsing-remitting multiple sclerosis. , 2011, Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria.

[21]  C. Pozzilli,et al.  Natalizumab treatment in multiple sclerosis: the experience of S. Andrea MS Centre in Rome , 2010, Neurological Sciences.

[22]  G. Comi,et al.  Three years of experience: the Italian registry and safety data update , 2010, Neurological Sciences.

[23]  G. Comi,et al.  Efficacy and tolerability of natalizumab in relapsing–remitting multiple sclerosis patients: a post-marketing observational study , 2010, Neurological Sciences.